Current filters:


Popular Filters

6601 to 6625 of 7184 results

Adding cetuximab following colon cancer surgery does not improve disease-free survival


Adding the drug cetuximab, the active ingredient of Erbitux from German drug major Merck KGaA (MRK: DE),…

cetuximabErbituxMerck KGaAOncologyPharmaceuticalResearch

EMA tightens conflicts-of-interests policies with immediate effect


The European Medicines Agency yesterday published its updated policy on conflicts of interests of the…


BASF and Catalent join forces to address NME bioavailability challenges


Privately-held USA-based Catalent Pharma Solutions has joined forces with German drug giant BASF (BAS:…

BASFCatalent PharmaGenericsPharmaceuticalResearch

Chinese colorectal cancer drug market forecast to grow to over $400 million in 2016


The colorectal cancer drug market in China will grow from a value of $261 million in 2011 to $404 million…

Asia-PacificAvastinErbituxMarkets & MarketingMerck KGaAOncologyPharmaceuticalRoche

Regional variations, but global sales force levels fell just 1.8% in 2011


Despite the current industry environment, there was a decline of just 1.8% in worldwide pharmaceutical…

GlobalMarkets & MarketingPharmaceutical

Roche presses on with takeover, despite further rejection by Illumina board


Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN)…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Bayer cancer drug candidate regorafenib improves survival in GIST


German drug major Bayer (BAY: DE) yesterday announced positive results from its Phase III trial GRID…


Eisai enters deals with Valeant and Minophagen


The European subsidiary of Japanese drug major Eisai (TYO: 4523) and PharmaSwiss, a division of Canada-based…

bexaroteneEisaiHalavenLicensingMarkets & MarketingMinophagenOncologyPharmaceuticalValeant Pharmaceuticals

Ph III albiglutide data in type 2 diabetes supports move to filing, says GSK


UK pharma giant GlaxoSmithKline plc (LSE: GSK) says that top-line results have been received from seven…

albiglutideDiabetesGlaxoSmithKlineHuman Genome SciencesPharmaceuticalResearch

FDA approves UCB drug Neupro for PD and RLS


Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that the US Food and Drug Administration…

NeuproNeurologicalNorth AmericaPharmaceuticalRegulationUCB

Synageva expands collaboration with Mitsubishi Tanabe Pharma


USA-based clinical-stage biopharma firm Synageva BioPharma (Nasdaq: GEVA) says it has expanded its previous…

LicensingMitsubishi TanabePharmaceuticalRare diseasesResearchSynageva BioPharma

Two targeted therapies act against Ewing's sarcoma tumors


A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma…

cixutumumabOncologyPharmaceuticalResearchTemsirolimus Injection

AstraZeneca collaborates with Amgen on five MAbs


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

GlaxoSmithKline ups stake in COPD drug partner Theravance


UK pharma giant GlaxoSmithKline (LSE: GSK) has increased its equity stake in USA-based Theravance (Nasdaq:…

GlaxoSmithKlineMergers & AcquisitionsPharmaceuticalTheravance

Eisai breast cancer drug still viewed as not cost effective by NICE


In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…


Roche to file for trastuzumab emtansine this year, on positive Ph III results


Swiss drug major Roche (ROG: SIX) says that top-line results of EMILIA, the first randomized Phase III…


FDA OKs pregnancy use of Novo Nordisk diabetes therapy Levemir


The US Food and Drug Administration has approved Levemir (insulin detemir [rDNA origin] injection), from…

DiabetesLevemirNorth AmericaNovo NordiskPharmaceuticalRegulation

Novartis QVA149 Ph III COPD studies meet primary endpoints


The first three QVA149 Phase III studies of QVA149 in the treatment of chronic obstructive pulmonary…

indacaterolNovartisPharmaceuticalResearchRespiratory and PulmonaryVectura

Poland breaking EU law by allowing unauthorized cheaper drugs


Polish legislation authorizing the placing on the market of foreign medicinal products lacking authorization…

EuropeGenericsLegalMarkets & MarketingPharmaceuticalRegulation

ViiV and Shionogi say dolutegravir meets primary endpoint in HIV


ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Government, academic and venture firms come together in March to fund translational and early-stage development


A host of new initiatives focused on funding translational research and early-stage companies brought…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

6601 to 6625 of 7184 results

Back to top